Spine BioPharma, Inc. — SEC Form D Filing

Spine BioPharma, Inc. filed an SEC Form D on June 5, 2026, reporting $385K raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
June 5, 2026
Amount reported
$385K
Round stage
Seed
Industry
Pharmaceuticals
Website
https://www.spinebiopharma.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Patients experience chronic low back pain and disability due to degenerative disc disease, and existing treatments often involve surgical interventions or opiates.

Solution

Spine BioPharma is developing SB-01, a non-surgical, non-opiate intradiscal injection therapy designed to relieve pain, restore function, and potentially slow or stop the progression of degenerative disc disease.

Verdict

Investors likely said yes because Spine BioPharma presented a targeted alternative to existing therapies for chronic low back pain, betting on a growing reluctance to use opioids and surgeries in favor of non-invasive treatments. This cleared because the unique approach of SB-01 captured interest, not because there was a well-defined commercial strategy or clear expansion plans. Limited upside arises from the crowded pain management landscape and regulatory hurdles that could delay product adoption and reimbursement.

Source: SEC EDGAR Form D filing